Royalty Pharma Q2 Adj EPS $0.84 Beats $0.83 Estimate, Sales $538.00M Miss $538.52M Estimate
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma (NASDAQ:RPRX) reported Q2 adjusted earnings of $0.84 per share, beating the analyst consensus estimate of $0.83 by 1.2%. This is a 20% increase from the same period last year. However, the company's quarterly sales of $538.00 million missed the analyst consensus estimate of $538.52 million by 0.10%, a 0.38% increase from last year.
August 08, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Royalty Pharma's Q2 earnings beat estimates but sales missed slightly. This mixed result may lead to neutral short-term price movement.
Royalty Pharma's earnings beat estimates, which is a positive signal for investors. However, the slight miss on sales could offset this positive sentiment. Therefore, a neutral short-term price movement is expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100